Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
1. SCNI reported $773K revenue, growing significantly from $284K last year. 2. R&D expenses dropped to $1.2M, down from $2.8M in 2024. 3. Net loss decreased to $4.1M, showing improved financial health. 4. Company raised $4.2M, strengthening cash position post-June 2025. 5. Advancements in psoriasis treatment and potential grants are underway.